(Combating New Coronary Pneumonia) Experts Talk Again about Plasma Therapy: Surveillance of Possible Risks Needs More Donations
China News Network, Beijing, March 22 (Reporter Sun Zifa) "Plasma smelting is just an exploratory treatment, and close monitoring of possible risks" "The main bottleneck at present is the plasma donation of new crown pneumonia patients" "Rehabilitation patients Blood donation has no special influence on itself "...
In a recent web interview organized by the Chinese Association of Science and Technology, a number of experts once again focused on plasma therapy for new coronary pneumonia, reminded monitoring of possible risks, called for more recovered patients to donate plasma, and actively explored effective potential treatments based on this.
Exploratory therapy requires close monitoring of possible risks
Huang Bo, deputy director of the Chinese Immunological Society, professor of the Department of Immunology of the Chinese Academy of Medical Sciences and Peking Union Medical College, and member of the National Crown Health Commission's new crown pneumonia expert group and chief physician of Beijing Ditan Hospital Infection Center, Jiang Rongmeng, said that the earliest attempts at plasma treatment during the rehabilitation period It goes back more than 100 years. In the past 20 years, in the major outbreaks such as SARS, H5N1 and H7N9 avian influenza, MERS, Ebola, there have been recovery plasma treatments. However, since its birth, scientists have also found that the concentration of plasma antibodies in practice Too low causes a series of problems such as poor efficacy. Plasma therapy is essentially antibody therapy. "We need to know enough about the complexity of antibodies and even the side that they may aggravate."
They pointed out that Chinese officials have added plasma therapy to their diagnosis and treatment programs, which are targeted at critically ill patients. At this stage, plasma therapy for patients with new coronary pneumonia has been promoted nationwide. Some patients have improved clinical indicators and symptoms, but there are also limited sources of therapeutic plasma, different antibody concentrations and activities in different people's plasma, and Non-neutralizing antibodies may contribute to limitations such as cytokine storms and other safety risks. Therefore, in the absence of vaccines and specific treatment drugs, plasma therapy is only an exploratory treatment method. It is currently recommended to be used in critically ill patients, and the possible risks are closely monitored.
Donating plasma during recovery period will not cause harm to the body
In response to the worries and concerns of donors about plasma donation, Yang Xiaoming, executive director of the Chinese Preventive Medicine Association and chairman of Sinopharm Group China Biotechnology Co., Ltd., said that unlike blood donation, donating plasma is a method of collecting blood by using a single plasma collection method. The plasma components are separated through a centrifuge, and red blood cells, platelets, etc. are also returned to the body. In normal human blood, plasma accounts for about 50%, while organic components such as potassium, sodium, chlorine, and various proteins in plasma account for only 8-10%. Most of the rest is water. Generally, the blood volume is within 48 hours after plasma donation. It will recover without causing damage to the body.
Huang Bo and Jiang Rongmeng pointed out that a normal blood donation of 200-400 ml at one time only accounts for 5-10% of the total blood volume of the human body. Generally, the blood plasma and inorganic salts lost by the human body can be penetrated into the blood vessels by the tissue fluid within 1-2 hours. Get supplemented; plasma proteins can also be recovered in one day; red blood cells and hemoglobin need to be recovered in 3-4 weeks.
Plasma therapy generally adopts the method of single plasma collection, and blood cells are transfused back into the blood donor. The whole process has strict process control, so it will not affect health. For patients with severe neo-coronary pneumonia, plasma therapy is used during the recovery period. Plasma is derived from those recovering from neo-coronary pneumonia. The blood donation of the recovered person has no special influence on himself, and there is no need to worry too much when donating blood.
Need more donations "Paste" Love to the end
Yang Xiaoming said that the recovery-specific plasma treatment for the epidemic was mainly aimed at severe and critically ill patients, and its early treatment results were very obvious. As of March 7, the Plasma Therapy Research Team of New Coronary Pneumonia Rescuers undertaken by Sinopharm China Biomedical has treated nearly 50 patients with severe illness in Wuhan. Six patients have been discharged. Most of them have improved and will be discharged in the near future.
Plasma therapy depends on plasma donation. At present, the main bottleneck is plasma donation for newcomers with new coronary pneumonia. As the number of recoverers continues to increase, "We call for more patients to be relieved of their anxiety and take the initiative to donate. One donation will be able to save The lives of 2-3 patients with new crown pneumonia. Let us relay for love together, 'slurry' love goes to the end ".
Huang Bo and Jiang Rongmeng said that currently, new crown pneumonia is gradually spreading worldwide, and it does not rule out the danger of turning into a chronic winter infectious disease and coexisting with humans for a long time. New coronal pneumonia is highly infectious, spreads rapidly, and has a complicated course, which brings problems to the treatment of the disease. "We need to solve the problem of the source of therapeutic plasma. More importantly, based on existing therapies, actively explore effective potential treatments. This is an important direction for the prevention and control of the global new crown pneumonia epidemic. "
According to Yang Xiaoming, in order to better use the plasma of the recovered patients to treat patients with severe and critically ill patients with new coronary pneumonia, after more and more cured patients agree to donate plasma, it is possible to consider using multiple plasmas from the recovered patients to prepare the new coronavirus human immunoglobulin preparation. This protein has undergone at least two virus inactivation processes and is not restricted by blood type matching pairs. It has higher safety, specificity, purity and practicality, and will be the best product for passive immunotherapy. It can accelerate its application process through the green channel. . (Finish)